Drug Shortage Report for SUPRAX
Report ID | 177149 |
Drug Identification Number | 00868965 |
Brand name | SUPRAX |
Common or Proper name | Cefixime for oral suspension |
Company Name | ODAN LABORATORIES LTD |
Market Status | MARKETED |
Active Ingredient(s) | CEFIXIME |
Strength(s) | 100MG |
Dosage form(s) | POWDER FOR SUSPENSION |
Route of administration | ORAL ORAL |
Packaging size | 50 mL |
ATC code | J01DD |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-12-01 |
Estimated end date | 2023-02-03 |
Actual end date | 2023-01-25 |
Shortage status | Resolved |
Updated date | 2023-01-26 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | info@odanlab.com Tel.: 1-800-387-9342 Fax: 1-800-329-6326 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2023-01-26 | English | Compare |
v6 | 2023-01-25 | French | Compare |
v5 | 2023-01-25 | English | Compare |
v4 | 2023-01-24 | French | Compare |
v3 | 2023-01-24 | English | Compare |
v2 | 2022-12-05 | French | Compare |
v1 | 2022-12-05 | English | Compare |
Showing 1 to 7 of 7